Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 549Neoplasms 384Carcinoma, Non-Small-Cell Lung 319Colorectal Neoplasms 290Lung Neoplasms 239Prostatic Neoplasms 219Carcinoma, Hepatocellular 212Stomach Neoplasms 158Pancreatic Neoplasms 151Leukemia, Myeloid, Acute 139Multiple Myeloma 130Uterine Cervical Neoplasms 127Recurrence 116Rectal Neoplasms 112Ovarian Neoplasms 105Neoplasm Metastasis 104Squamous Cell Carcinoma of Head and Neck 97Head and Neck Neoplasms 89Esophageal Neoplasms 85Triple Negative Breast Neoplasms 84Glioblastoma 80Small Cell Lung Carcinoma 79Endometrial Neoplasms 79Colonic Neoplasms 78Brain Neoplasms 78Melanoma 69Precursor Cell Lymphoblastic Leukemia-Lymphoma 66Hematologic Neoplasms 64Glioma 62Motor Activity 60

Interventions

ensartinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × ALK-positive Advanced NSCLC × Clear all
NCT06785584 2025-01-21

Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma :A Multicenter, Real-World Clinical Study

Fujian Medical University Union Hospital

Phase 4 Not yet recruiting
30 enrolled
Thoracic

ALK-positive Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡